Research use only · Lyophilised material · Not a medicine · Not for human or veterinary use · Disclaimer

Comparison · not a ranking

ARA-290 compared with TB-500

ARA-290 and TB-500 are separate catalogue items. They are not interchangeable.A CoA for every lot; each vial carries a printed lot number that matches it. Request yours and we email it within 2 hours. Research use only. Not a medicine.

Last verified 9 Nov 2026. UK prices checked daily.

ARA-290 and TB-500 are two distinct catalogue compounds. ARA-290 is a 11-residue peptide, while TB-500 is a 7-residue peptide. ARA-290: C51H84N16O21, 1257.3 g/mol, CAS 1208243-50-8. TB-500: C38H68N10O14, 889.0 g/mol, CAS 885340-08-9. By sequence, ARA-290 is pGlu-Glu-Gln-Leu-Glu-Arg-Ala-Leu-Asn-Ser-Ser and TB-500 is Ac-Leu-Lys-Lys-Thr-Glu-Thr-Gln. In short, their molecular weights differ by about 368.3 g/mol; their sequences differ in length (11 versus 7 residues). Each has its own reference record, which lists the source for every figure above. Sable Peptides, a UK supplier operating since 2019, lists both as lyophilised research material; every vial carries a lot number and a certificate of analysis exists for every lot — request yours at /coa-request and we email it within 2 hours. This intro compares identity only and ranks neither compound. Research use only. Not a medicine. Not for human or veterinary use.

Sources: pubchem.ncbi.nlm.nih.gov · pubchem.ncbi.nlm.nih.gov

/ref/ara-290 · /ref/tb-500

ARA-290 and TB-500 are two records in the Sable Peptides catalogue at https://www.sablepeptides.co.uk/versus/ara-290/tb-500. These prices are both Sable catalogue prices. They are not a comparison with another shop. This page does not rank either compound. Each page shows the catalogue price. A market comparison appears only when an exact, current, approved listing for that size is on record. Only a row with the same amount is a like-for-like price.

Research use only. Not a medicine. Not for human or veterinary use. Disclaimer

Same amount, both catalogue prices. Not a comparison with another seller.
AmountARA-290TB-500
5 mg£25.99£9.00

Reference facts

FactARA-290TB-500
Molecular weight1257.3 g/mol889.0 g/mol
Molecular formulaC51H84N16O21C38H68N10O14
CAS number1208243-50-8885340-08-9
Compound classpeptidepeptide

Sources: pubchem.ncbi.nlm.nih.gov, pubchem.ncbi.nlm.nih.gov Verified 2026-11-09

Category
ARA-290Repair
TB-500Repair
Research use only
ARA-290Yes
TB-500Yes
Vials
ARA-2902
TB-5005
Record
ARA-290ara-290
TB-500tb-500

ARA-290 · TB-500

Questions this page answers

How does ARA-290 compare with TB-500?
Same vial amounts are shown side by side with each catalogue price. Different amounts are not treated as the same price. No effect is compared, and another seller is not compared.
Which is better?
This page does not say. It does not rank safety, strength, or effect.
What is the lowest catalogue price per mg for ARA-290 and TB-500?
ARA-290: £2.19/mg on the 16 mg vial (£35.00). TB-500: £1.10/mg on the 10 mg vial (£10.99). Different compounds; this is a catalogue price fact, not a ranking.
How many vial sizes are listed for each?
ARA-290: 5 mg, 16 mg. TB-500: 2 mg, 5 mg, 10 mg, 15 mg, 20 mg.

Both compounds

Related research

In-depth comparison

Sable research note. Updated 2026-10-10. Research use only.

Short answer

ARA-290 (cibinetide) and TB-500 are different compounds. ARA-290 (cibinetide) is an erythropoietin-derived linear peptide; TB-500 is a thymosin beta-4 fragment peptide. By PubChem's computed values, ARA-290 (cibinetide) (1257.3 g/mol) is about 1.4 times the mass of TB-500 (889 g/mol). Sable lists both as freeze-dried research material. Research use only: neither is sold as a medicine, and neither is for use in people or animals.

At a glance

ARA-290 (cibinetide) TB-500
Class erythropoietin-derived linear peptide thymosin beta-4 fragment peptide
Formula (PubChem) C51H84N16O21 C38H68N10O14
Molecular weight (PubChem, g/mol) 1257.3 889
PubChem CID 91810664 62707662
Sable form freeze-dried powder freeze-dried powder

Structure

ARA-290 (cibinetide) is an 11-residue linear peptide (pGlu-EQLERALNSS) modelled on helix B of erythropoietin. PubChem CID 91810664 lists the formula C51H84N16O21 and a computed molecular weight of 1257.3 g/mol (https://pubchem.ncbi.nlm.nih.gov/compound/91810664).

TB-500 is the acetylated heptapeptide Ac-LKKTETQ, corresponding to the actin-binding region (residues 17-23) of thymosin beta-4; it is not the full 43-residue protein. PubChem CID 62707662 lists the formula C38H68N10O14 and a computed molecular weight of 889 g/mol (https://pubchem.ncbi.nlm.nih.gov/compound/62707662).

Both are peptides, so the meaningful structural differences are sequence, length and modifications rather than chemical category. Differences in residue count, terminal capping (acetylation or amidation), non-natural amino acids and lipid side chains all change molecular weight, solubility and how a compound behaves in an assay. Matching like with like at the structural level is the first step before any comparison of experimental results.

Molecular weight in context

On PubChem's computed figures, ARA-290 (cibinetide) is a mid-sized peptide (1,000 to 3,000 g/mol) and TB-500 is a small molecule-sized compound (under 1,000 g/mol). The difference is 368.3 g/mol.

Molecular weight matters in practice for three reasons. First, one milligram of a lighter compound contains more molecules than one milligram of a heavier one, so equal milligram amounts are not equal molar amounts. Second, the expected mass is what identity testing checks against: mass spectrometry on a certificate of analysis should report a value consistent with the formula. Third, salt forms (for example acetate or TFA counter-ions) and metal complexes add mass that a free-base figure does not show, so a certificate may legitimately quote a slightly different value from a database entry.

Class and research context

ARA-290 (cibinetide): studied as a ligand of the innate repair receptor (EPOR/CD131 heteromer) without the haematopoietic activity of erythropoietin.

TB-500: studied as a fragment of the actin-sequestering protein thymosin beta-4.

These descriptions summarise how each compound is characterised in the published literature and in chemical databases. They are not claims about effects in people, and Sable gives no administration or medical-use information for either compound. Readers who need mechanism detail should go to the primary sources and the PubChem literature sections linked below.

How to compare them fairly

  • Compare identity first: formula, sequence and expected mass, then purity.
  • Compare amounts only at the same milligram size, remembering that equal milligrams are not equal moles.
  • Ask for the certificate of analysis for the specific batch. At Sable, every vial is released at ≥99% purity by HPLC with identity checked against the expected mass, and certificates are available for every lot.
  • Treat a search pairing as a navigation habit, not as evidence that two compounds do the same thing.

Sable listings

Vial sizes as listed on 2026-10-10. Each product page carries the current catalogue details.

ARA-290 (cibinetide) (compound guide: https://www.sablepeptides.co.uk/ara-290-uk): - ARA-290 5 mg: https://www.sablepeptides.co.uk/product/ara-290-5mg - ARA-290 16 mg: https://www.sablepeptides.co.uk/product/ara-290-16mg

TB-500 (compound guide: https://www.sablepeptides.co.uk/tb-500-uk): - TB-500 10 mg: https://www.sablepeptides.co.uk/product/tb-500-10mg - TB-500 2 mg: https://www.sablepeptides.co.uk/product/tb-500-2mg - TB-500 5 mg: https://www.sablepeptides.co.uk/product/tb-500-5mg - TB-500 20 mg: https://www.sablepeptides.co.uk/product/tb-500-20mg - TB-500 15 mg: https://www.sablepeptides.co.uk/product/tb-500-15mg

Peptide vials contain freeze-dried powder only; bacteriostatic water is listed separately. Research use only. Not a medicine. Not for human or veterinary use.

Sources

  • PubChem, ARA-290 (cibinetide): https://pubchem.ncbi.nlm.nih.gov/compound/91810664
  • PubChem, TB-500: https://pubchem.ncbi.nlm.nih.gov/compound/62707662
  • Sable price index and methodology: https://www.sablepeptides.co.uk/pricing/methodology
  • Sable quality and certificate requests: https://www.sablepeptides.co.uk/quality

Comparison questions

What is the difference between ARA-290 (cibinetide) and TB-500?

ARA-290 (cibinetide) and TB-500 are different compounds. ARA-290 (cibinetide) is an erythropoietin-derived linear peptide; TB-500 is a thymosin beta-4 fragment peptide. By PubChem's computed values, ARA-290 (cibinetide) (1257.3 g/mol) is about 1.4 times the mass of TB-500 (889 g/mol). Sable lists both as freeze-dried research material. Research use only: neither is sold as a medicine, and neither is for use in people or animals.

What are the molecular weights of ARA-290 (cibinetide) and TB-500?

ARA-290 (cibinetide): 1257.3 g/mol (PubChem CID 91810664); TB-500: 889 g/mol (PubChem CID 62707662).

Are these sold for use in people?

No. Both are laboratory research material only: not medicines, and not for use in people or animals. No administration or medical-use information is provided.

ARA-290 and TB-500 are different research compounds, compared here by vial sizes, price per mg and published identifiers. Sable Peptides sells ARA-290 from £25.99 and TB-500 from £9.00. Every lot has an HPLC and mass-spectrometry Certificate of Analysis, emailed within 2 hours of a request.

Updated